SLC5A2 and heart failure: In this study, compared to the placebo groups, canagliflozin, ertugliflozin, and sotagliflozin (a dual SGLT-2 and 1 inhibitor) have been associated with a reduction in all-cause mortality; canagliflozin, dapagliflozin, empagliflozin, ertugliflozin, and sotagliflozin with a reduction in cardiovascular mortality; canagliflozin, dapagliflozin, empagliflozin, ertugliflozin, and sotagliflozin with a reduction in hospitalizations for heart failure; and dapagliflozin, empagliflozin, canagliflozin, sotagliflozin, and ertugliflozin with a reduction in the renal composite outcome [208].